Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.74 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.74 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | DAO | P14920 | 3/20 | 0.42 |
| ▸ | GSK3B | P49841 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.34 |
| ▸ | CES1 | P23141 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Chlorobenzene SCHEMBL28758781 | 0.85 | MAPT (0.56) | MAPTNPSR1TP53HPGDPOLB | |
| SCHEMBL6826333 | 0.83 | DAO (0.59) | MAPTNPSR1HPGDPOLBHTT | |
| SCHEMBL24956336 | 0.82 | HPGD (0.67) | MAPTNPSR1HPGDPOLBHTT | |
| SCHEMBL11636348 | 0.82 | MAPT (0.71) | MAPTNPSR1TP53HPGDPOLB | |
| SCHEMBL19328795 | 0.82 | MAPT (0.50) | MAPTNPSR1TP53HPGDPOLB | |
| SCHEMBL13267640 | 0.82 | MAPT (0.50) | MAPTNPSR1TP53HPGDPOLB | |
| SCHEMBL8180294 | 0.80 | NPSR1 (0.48) | MAPTNPSR1HPGDPOLBHTT | |
| SCHEMBL1363923 | 0.80 | MAPT (0.69) | MAPTNPSR1TP53HPGDPOLB | |
| SCHEMBL10208115 | 0.79 | HPGD (0.50) | MAPTNPSR1TP53HPGDPOLB | |
| SCHEMBL13125587 | 0.79 | MAPT (0.67) | MAPTNPSR1TP53HPGDPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718607-B2 | Atypical coupling method for the preparation of 1,2-di(thiophen-2-yl)ethene-1,2-diol compounds via a Cu(II) catalyst | QATAR UNIVERSITY (QA) | 2023-08-08 | — | — | US | disclosed |
| EP-2315751-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | Amgen Inc. (US) | 2011-05-04 | — | — | EP | disclosed |
| US-20110086834-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | AMGEN INC. (US) | 2011-04-14 | — | — | US | disclosed |
| US-20110086834-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | AMGEN INC. (US) | 2011-04-14 | — | — | US | disclosed |
| US-20110086834-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | AMGEN INC. (US) | 2011-04-14 | — | — | US | disclosed |
| WO-2009158011-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | AMGEN INC. (US) | 2009-12-30 | — | — | WO | disclosed |
| WO-2009158011-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | AMGEN INC. (US) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718607-B2 | Atypical coupling method for the preparation of 1,2-di(thiophen-2-yl)ethene-1,2-diol compounds via a Cu(II) catalyst | AP2A2, AP2A1, DNM2 | MAPT 3574/4885NPSR1 3273/4885TP53 4448/4885 |
| US-20110086834-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | NFKBIA, MAP3K1, MAP3K2 | MAPT 2056/4885NPSR1 3540/4885TP53 1159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.